A share price of Genmab ADR [GMAB] is currently trading at $21.30, up 1.82%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The GMAB shares have gain 12.11% over the last week, with a monthly amount glided 5.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Genmab ADR [NASDAQ: GMAB] stock has seen the most recent analyst activity on February 13, 2025, when Leerink Partners upgraded its rating to a Outperform but kept the price target unchanged to $27 for it. JP Morgan downgraded its rating to a Neutral. RBC Capital Mkts upgraded its rating to a Outperform. BMO Capital Markets upgraded its rating to Outperform for this stock on February 23, 2024, and upped its price target to $48. In a note dated January 22, 2024, Citigroup downgraded an Sell rating on this stock.
Genmab ADR experienced fluctuations in its stock price throughout the past year between $18.64 and $31.88. Currently, Wall Street analysts expect the stock to reach $31 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $21.30 at the most recent close of the market. An investor can expect a potential return of 45.54% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
Trailing Twelve Months sales for Genmab ADR [NASDAQ:GMAB] were 3.12B which represents 36.55% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.33%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.15 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.10 points at the first support level, and at 20.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.40, and for the 2nd resistance point, it is at 21.51.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Genmab ADR [NASDAQ:GMAB] is 5.25. As well, the Quick Ratio is 5.24, while the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 4.34, the price to book ratio is 2.66 and price to earnings (TTM) ratio is 12.16.
